Inhibitory activity of limonoids from Khaya grandifoliola C.DC (Meliaceae) against hepatitis C virus infection in vitro | ||
| Avicenna Journal of Phytomedicine | ||
| دوره 11، شماره 4، مهر و آبان 2021، صفحه 353-366 اصل مقاله (911.21 K) | ||
| نوع مقاله: Original Research Article | ||
| شناسه دیجیتال (DOI): 10.22038/ajp.2020.17215 | ||
| نویسندگان | ||
| Kouam Fondjo Arnaud* 1؛ Njayou Frédéric Nico2؛ Yuan Fei3؛ Babayemi Olawale Oladejo4؛ He Hongtao3؛ Mkounga Pierre5؛ Moundipa Fewou Paul2 | ||
| 1Department of Biomedical Sciences Faculty of Health Sciences University of Buea South West Region, Buea, Cameroon | ||
| 2Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science, University of Yaoundé 1, PO Box 812, Yaoundé, Cameroon | ||
| 3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China | ||
| 4Department of Microbiology, Federal University of Technology, P.M.B 704, Akure, Ondo State, Nigeria | ||
| 5Laboratory of Physical Chemistry and Phytochemistry, Department of Organic Chemistry, University of Yaoundé 1, PO Box 812, Yaoundé, Cameroon | ||
| چکیده | ||
| Objective: A fraction from Khaya grandifoliola has recently been shown to inhibit hepatitis C virus (HCV) infection and three limonoids (17-epi-methyl-6-hydroxylangolensate, 7-deacetoxy-7-oxogedunin and 7-deacetoxy-7R-hydroxygedunin) were purified from this fraction. The present study aimed at assessing the inhibitory effect of these limonoids on HCV using cell-culture derived HCV (HCVcc) system. Materials and Methods: Cytotoxic effects of the limonoids on Huh7.5 cells were assessed by MTT assay. Huh7.5 cells were transfected with RNA transcripts of the plasmid Jc1/GLuc2a, carrying a Gaussia luciferase reporter gene to rescue the HCVcc particles which were used to infect naïve cells in the presence or absence of the studied limonoids during 72 hr. Infection and replication rates were monitored by luciferase reporter assay and immunofluorescence assay (IFA) while cellular gene expression was analyzed by western blot, respectively. Results: The limonoids inhibited HCV infection mostly by targeting entry and replication stage. Their inhibitory effect on entry step, comparable to that of anti-CD81 antibody, was related to the blocking of CD81 receptor. In the replication step, the limonoids decreased the expression of NS5B similar to danoprevir. These compounds also significantly decreased but up-regulated the expression of Class-III phosphatidylinositol 4-kinase alpha and 2’,5’-oligoadenylate synthase-3, respectively. Conclusion: The present findings suggest that limonoids from K. grandifoliola are potential anti-HCV agents and may offer an advantage in the treatment of HCV infection. | ||
| کلیدواژهها | ||
| Khaya grandifoliola؛ Limonoids؛ Anti-HCV infection؛ Class III phosphatidylinositol 4-kinase alpha؛ 2’,5’- oligoadenylate synthase-3 | ||
| مراجع | ||
|
Averhoff FM, Glass N, Holtzman D. 2012. Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Clin. Infect. Dis. 55, S10–S15. Bartenschlager R, Cosset FL, Lohmann V, 2010. Hepatitis C virus replication cycle. J Hepatol, 53: 583–585. Bartenschlager R, Sparacio S. 2007. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res, 127: 195–207. Belouzard S, Cocquerel L, Dubuisson J. 2011. Hepatitis C virus entry into the hepatocyte. Open Life Sci, 6. Bianco A, Reghellin V, Donnici L, Fenu S, Alvarez R, Baruffa C, Peri F, Pagani M, Abrignani S, Neddermann P, De Francesco R. 2012. Metabolism of Phosphatidylinositol 4-Kinase IIIα-Dependent PI4P Is Subverted by HCV and Is Targeted by a 4-Anilino Quinazoline with Antiviral Activity. PLoS Pathog, 8: e1002576. Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornella Taracido I, Baryza J, Tallarico J, Joberty G, Bantscheff M, Schirle M, Bouwmeester T, Mathy JE, Lin K, Anti-HCV effect of Khaya grandifoliola AJP, Vol. 11, No. 4, Jul-Aug 2021 365 Compton T, Labow M, Wiedmann B, Gaither LA. 2009. Class III Phosphatidylinositol 4- Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication. J Virol, 83: 10058–10074. Cheng YL, Lan KH, Lee WP, Tseng SH, Hung LR, Lin HC, Lee FY, LeeSD, Lan KH. 2013. Amiodarone inhibits the entry and assembly steps of hepatitis C virus life cycle. Clin Sci, 125: 439–448. Choo Q, Kuo G, Weiner A, Overby L, Bradley D, Houghton M. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244: 359–362. Galani BRT, Sahuc ME, Sass G, Njayou FN, Loscher C, Mkounga P, Deloison G, Brodin, P, Rouillé Y, Tiegs G, Séron K, Moundipa PF. 2016. Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. Arch Virol, 161: 1169–1181. Gottwein JM, Scheel TKH, Hoegh AM, Lademann JB, Eugen–Olsen J, Lisby G, Bukh J. 2007. Robust Hepatitis C Genotype 3a Cell Culture Releasing Adapted Intergenotypic 3a/2a (S52/JFH1) Viruses. Gastroenterology, 133: 1614–1626. Herker E, Harris C, Hernandez C, Carpentier A, Kaehlcke K, Rosenberg AR, Farese RV, Ott M. 2010. Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat Med, 16: 1295–1298. Holzer M, Ziegler S, Albrecht B, Kronenberger B, Kaul A, Bartenschlager R, Kattner L, Klein C. Hartmann R. 2008a. Identification of Terfenadine as an Inhibitor of Human CD81-Receptor HCV-E2 Interaction: Synthesis and Structure Optimization. Molecules, 13: 1081–1110. Holzer M, Ziegler S, Neugebauer A, Kronenberger B, Klein CD, Hartmann RW. 2008b. Structural Modifications of Salicylates: Inhibitors of Human CD81‐ Receptor HCV‐E2 Interaction. Arch Pharm, (Weinheim) 341: 478–484. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Ye J. 2007. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci, 104: 5848– 5853. Keating GM. 2015. Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C. Drugs, 75: 675–685. Kouam AF, Yuan F, Njayou FN, He H, Tsayem RF, Oladejo BO, Song F, Moundipa PF, Gao GF. 2017. Induction of Mkp-1 and Nuclear Translocation of Nrf2 by Limonoids from Khaya grandifoliola C.DC Protect L-02 Hepatocytes against Acetaminophen-Induced Hepatotoxicity. Front Pharmacol, 8. Kronenberger B. 2001. Interferon alfa downregulates CD81 in patients with chronic hepatitis C. Hepatology, 33: 1518–1526. Kumthip K, Maneekarn N. 2015. The role of HCV proteins on treatment outcomes. Virol J, 12. Lehmann E, El-Tantawy WH, Ocker M, Bartenschlager R, Lohmann V, Hashemolhosseini S, Tiegs G, Sass G. 2010. The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology, 51: 398–404. Lin LT, Hsu WC, Lin CC. 2014. Antiviral Natural Products and Herbal Medicines. J Tradit Complement Med, 4: 24–35. Lindenbach BD. 2009. Measuring HCV Infectivity Produced in Cell Culture and In Vivo, in: Tang, H. (Ed.), Hepatitis C: Methods and Protocols. Humana Press, Totowa, NJ, pp. 329–336. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete Replication of Hepatitis C Virus in Cell Culture. Science, 309: 623- 626. Liu D, Ji J, Ndongwe TP, Michailidis E, Rice CM, Ralston R, Sarafianos SG. 2015. Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach. Antimicrob Agents Chemother, 59: 3482– 3492. Ly KN, Miniño AM, Liu SJ, Roberts H, Hughes EM, Ward JW, Jiles RB. 2020. Deaths Associated With Hepatitis C Virus Infection Among Residents in 50 States and the District of Columbia, 2016–2017. Clin Infect Dis 71: 1149–1160. Mohd Hanafiah, K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol Baltim Md, 57: 1333–1342. Fondjo Kouam et al. AJP, Vol. 11, No. 4, Jul-Aug 2021 366 Moradpour D, Penin F, Rice CM. 2007. Replication of hepatitis C virus. Nat Rev Microbiol, 5: 453–463. Njouom R, Texier G, Fontanet A, 2015. O-02: Prevalence of hepatitis B, hepatitis C and hepatitis D virus infections in Cameroon: results from a national population based survey (The ANRS 12289 project). J Viral Hepat, 22: 1–2. Phan T, Beran RKF, Peters C, Lorenz IC, Lindenbach BD. 2009. Hepatitis C Virus NS2 Protein Contributes to Virus Particle Assembly via Opposing Epistatic Interactions with the E1-E2 Glycoprotein and NS3-NS4A Enzyme Complexes. J Virol, 83: 8379–8395. Sarrazin C, Zeuzem S. 2010. Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection. Gastroenterology, 138: 447–462. Sen GC, Sarkar SN. 2007. The InterferonStimulated Genes: Targets of Direct Signaling by Interferons, Double-Stranded RNA, and Viruses, in: Pitha, P.M. (Ed.), Interferon: The 50th Anniversary. Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 233–250. Tellinghuisen TL, Rice CM. 2002. Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol, 5: 419– 427. Tietcheu Galani BR, Njouom R, Moundipa PF, 2016. Hepatitis C in Cameroon: What is the progress from 2001 to 2016? J Transl Intern Med, 4: 162–169. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a clon | ||
|
آمار تعداد مشاهده مقاله: 6,568 تعداد دریافت فایل اصل مقاله: 541 |
||